CORD-19:ee0a7632371a08727d41e55aad7d621daeceef7d / 138045-138224 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"T76774","span":{"begin":0,"end":179},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The rare aggressive cases of HCL that are resistant to standard therapy with BRAF oncoprotein inhibitors have prompted the search for additional new HCL associated gene mutations."}

    CORD-19_Custom_license_subset

    {"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T8","span":{"begin":0,"end":179},"obj":"Sentence"}],"text":"The rare aggressive cases of HCL that are resistant to standard therapy with BRAF oncoprotein inhibitors have prompted the search for additional new HCL associated gene mutations."}

    CORD-19-PD-HP

    {"project":"CORD-19-PD-HP","denotations":[{"id":"T336","span":{"begin":9,"end":19},"obj":"Phenotype"}],"attributes":[{"id":"A336","pred":"hp_id","subj":"T336","obj":"http://purl.obolibrary.org/obo/HP_0000718"}],"text":"The rare aggressive cases of HCL that are resistant to standard therapy with BRAF oncoprotein inhibitors have prompted the search for additional new HCL associated gene mutations."}

    CORD-19-PD-MONDO

    {"project":"CORD-19-PD-MONDO","denotations":[{"id":"T794","span":{"begin":29,"end":32},"obj":"Disease"},{"id":"T795","span":{"begin":149,"end":152},"obj":"Disease"},{"id":"T6261","span":{"begin":29,"end":32},"obj":"Disease"},{"id":"T29844","span":{"begin":149,"end":152},"obj":"Disease"}],"attributes":[{"id":"A794","pred":"mondo_id","subj":"T794","obj":"http://purl.obolibrary.org/obo/MONDO_0018935"},{"id":"A795","pred":"mondo_id","subj":"T795","obj":"http://purl.obolibrary.org/obo/MONDO_0018935"},{"id":"A92180","pred":"mondo_id","subj":"T6261","obj":"http://purl.obolibrary.org/obo/MONDO_0018935"},{"id":"A92103","pred":"mondo_id","subj":"T29844","obj":"http://purl.obolibrary.org/obo/MONDO_0018935"}],"text":"The rare aggressive cases of HCL that are resistant to standard therapy with BRAF oncoprotein inhibitors have prompted the search for additional new HCL associated gene mutations."}